Going Digital - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Going Digital
Software and online monitoring are helping the pharmaceutical industry improve its corrective and preventive action programs. This article contains bonus online material.


Pharmaceutical Technology
Volume 34, Issue 9, pp. 36-40


(PHOTO: COMSTOCK IMAGES, GETTY IMAGES)
Pharmaceutical manufacturing processes continue to evolve, periodically embracing technological developments such as disposable components and regulatory initiatives such as process analytical technology (PAT). These changes have improved many operations, yet the top two causes of deviations—human error and equipment failure—remain the same. These factors create anywhere from 50% to two-thirds of manufacturers' headaches. How could companies remove them from the equation? One possible solution is automation.

Drugmakers use corrective and preventive action (CAPA) programs to address deviations, modify procedures to prevent their recurrence, and measure the effectiveness of these modifications. Automating CAPA processes with software can help manufacturers find the best ways to resolve production problems and, ideally, eliminate deviations altogether.

Knowledge is power

Personnel must know as much as possible about a deviation to resolve it effectively through a CAPA program. Most drug companies have a software application system dedicated to tracking production problems and helping personnel figure out how to avoid them in the future. To enable thorough investigations, this system must receive accurate information about the manufacturing process. But if personnel enter data into the system manually, the opportunity for human error increases, and it becomes difficult to categorize deviations correctly and find their root causes. These difficulties can delay a product s release for shipping.


Employees prepare for cell-culture transfer from a seed bioreactor into a perfusion bioreactor. (IMAGE IS COURTESY OF PFIZER)
Automation that captures data and integrated software that facilitates the tracking and trending of actions and commitments are important tools for supporting a successful CAPA program. "With the move to at-line or on-line data-capture tools, the capture of events and excursions during processes is achieved more readily through automation," says William (Al) Kentrup, vice-president of manufacturing and supplier quality assessments at Pfizer (New York). Integrating the related event logs into appropriate CAPA software allows a company to manage the manufacturing process, including product disposition and resource allocations, effectively.

On the other hand, sometimes data-capture tools are too effective for their own good. "In today's environment, the ability to capture data and events can exceed the ability to assess them and react appropriately," says Kentrup. But automation or software tools can help manufacturers convert data into knowledge easily, especially in highly automated or complex processes such as packaging operations.

In addition to PAT tools that enable on-line monitoring, an automated, centralized quality-control system also helps address the challenge of getting consistent, granular data, says Tim Mohn, industry principal at Sparta Systems (Holmdel, NJ). Integrating the CAPA program with an overall quality-management solution can provide a comprehensive view of the process and facilitate root-cause analysis and trending.

Close the loop

Trending of data, a crucial part of the CAPA process, allows a manufacturer to assess its performance in comparison with established standards. Trending deserves more of drugmakers' attention because it allows them to determine how effective their corrective actions are in preventing the recurrence of deviations. Over time, pharmaceutical manufacturers have become skilled at identifying root causes and developing preventive actions for deviations. But companies often do not follow up by performing the appropriate tracking, trending, and effectiveness checks, says Susan Schniepp, vice-president of OSO BioPharmaceuticals Manufacturing (Albuquerque, NM) and a member of Pharmaceutical Technology's editorial advisory board. This lack of continuity can allow a deviation to recur if the preventive action did not address the problem directly. Automation can make it easier for companies to track manufacturing operations and perform effectiveness checks, which are crucial steps for closing the loop of the CAPA process.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: Pharmaceutical Technology,
Click here